WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Join the Society for Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
The Journal of Neuroscience, August 22, 2007, 27(34):9220-9232; doi:10.1523/JNEUROSCI.2617-07.2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danzer, K. M.
Right arrow Articles by Kostka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danzer, K. M.
Right arrow Articles by Kostka, M.

 Previous Article  |  Next Article 

Neurobiology of Disease
Different Species of {alpha}-Synuclein Oligomers Induce Calcium Influx and Seeding

Karin M. Danzer,1 Dorothea Haasen,2 Anne R. Karow,1 Simon Moussaud,1 Matthias Habeck,3 Armin Giese,3 Hans Kretzschmar,3 Bastian Hengerer,1 and Marcus Kostka1

1Central Nervous System Research and 2Integrated Drug Discovery, Boehringer Ingelheim Pharma, 88397 Biberach, Germany, and 3Zentrum für Neuropathologie und Prionforschung, Ludwig-Maximilians Universität München, 81377 München, Germany

Correspondence should be addressed to either Karin Danzer or Marcus Kostka, Central Nervous System Research, Boehringer Ingelheim Pharma GmbH, Birkendorferstrasse 65, 88397 Biberach, Germany. Email: Karin.Danzer{at}bc.boehringer-ingelheim.com or Email: Marcus.Kostka{at}bc.boehringer-ingelheim.com

Aggregation of {alpha}-synuclein ({alpha}-syn) has been linked to the pathogenesis of Parkinson's disease (PD) and other neurodegenerative diseases. Increasing evidence suggests that prefibrillar oligomers and protofibrils, rather than mature fibrils of {alpha}-syn, are the pathogenic species in PD. Despite extensive effort on studying oligomerization of {alpha}-syn, no studies have compared different oligomer species directly on a single-particle level and investigated their biological effects on cells. In this study, we applied a novel highly sensitive single molecule detection system that allowed a direct comparison of different oligomer types. Furthermore, we studied biological effects of different oligomer types on cells. For this purpose, we developed new oligomerization protocols, that enabled the use of these different oligomers in cell culture. We found that all of our three aggregation protocols resulted in heterogeneous populations of oligomers. Some types of oligomers induced cell death via disruption of cellular ion homeostasis by a presumably pore-forming mechanism. Other oligomer types could directly enter the cell resulting in increased {alpha}-syn aggregation. Based on our results, we propose that under various physiological conditions, heterogeneous populations of oligomeric forms will coexist in an equilibrium. These different oligomer types lead directly or indirectly to cell damage. Our data indicate that inhibition of early {alpha}-syn aggregation events would consequently prevent all {alpha}-syn oligomer related toxicities. This has important implications for the development of disease-modifying drugs for the treatment of PD and other synucleinopathies.

Key words: Parkinson's disease; neurodegeneration; {alpha}-synuclein; pore-formation; oligomers; toxicity

Received March 22, 2007; accepted June 21, 2007.

Correspondence should be addressed to either Karin Danzer or Marcus Kostka, Central Nervous System Research, Boehringer Ingelheim Pharma GmbH, Birkendorferstrasse 65, 88397 Biberach, Germany. Email: Karin.Danzer{at}bc.boehringer-ingelheim.com or Email: Marcus.Kostka{at}bc.boehringer-ingelheim.com




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
S. Vale
Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come?
Experimental Biology and Medicine, August 1, 2008; 233(8): 941 - 951.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N.-Y. Zhang, Z. Tang, and C.-W. Liu
{alpha}-Synuclein Protofibrils Inhibit 26 S Proteasome-mediated Protein Degradation: UNDERSTANDING THE CYTOTOXICITY OF PROTEIN PROTOFIBRILS IN NEURODEGENERATIVE DISEASE PATHOGENESIS
J. Biol. Chem., July 18, 2008; 283(29): 20288 - 20298.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
Y. Du, X. Li, D. Yang, X. Zhang, S. Chen, K. Huang, and W. Le
Multiple Molecular Pathways Are Involved in the Neuroprotection of GDNF Against Proteasome Inhibitor Induced Dopamine Neuron Degeneration In Vivo
Experimental Biology and Medicine, July 1, 2008; 233(7): 881 - 890.
[Abstract] [Full Text] [PDF]


-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-